Summary:
- The FDA has granted Priority Review to Insmed’s supplemental New Drug Application (sNDA) for ARIKAYCE (amikacin liposome inhalation suspension), targeting an expanded patient population with Mycobacterium avium complex (MAC) lung disease.
- This regulatory milestone highlights advancements in clinical pharmacology and the development of targeted inhaled therapies for chronic, refractory pulmonary infections.